Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Nature. 2018 Sep;561(7722):189-194. doi: 10.1038/s41586-018-0483-6. Epub 2018 Sep 12.

Optimized arylomycins are a new class of Gram-negative antibiotics.

Author information

1
Department of Infectious Diseases, Genentech, South San Francisco, CA, USA. smith.peter@gene.com.
2
Department of Discovery Chemistry, Genentech, South San Francisco, CA, USA.
3
Department of Infectious Diseases, Genentech, South San Francisco, CA, USA.
4
Department of Translational Immunology, Genentech, South San Francisco, CA, USA.
5
Department of Chemistry, Wuxi AppTec, Shanghai, China.
6
Department of Drug Metabolism and Pharmacokinetics, Genentech, South San Francisco, CA, USA.
7
RQx Pharmaceuticals, La Jolla, CA, USA.
8
Retrovirox, San Diego, CA, USA.
9
Department of Structural Biology, Genentech, South San Francisco, CA, USA.
10
Vertex, San Diego, CA, USA.
11
Department of Microchem Proteomics, Genentech, South San Francisco, CA, USA.
12
Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, CA, USA.
13
Aduro Biotech, Berkeley, CA, USA.
14
FLX Bio, South San Francisco, CA, USA.
15
Department of Bioinformatics and Computational Biology, Genentech, South San Francisco, CA, USA.
16
Department of Infectious Diseases, Genentech, South San Francisco, CA, USA. heise.christopher@gene.com.
17
Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, CA, USA. heise.christopher@gene.com.

Abstract

Multidrug-resistant bacteria are spreading at alarming rates, and despite extensive efforts no new class of antibiotic with activity against Gram-negative bacteria has been approved in over fifty years. Natural products and their derivatives have a key role in combating Gram-negative pathogens. Here we report chemical optimization of the arylomycins-a class of natural products with weak activity and limited spectrum-to obtain G0775, a molecule with potent, broad-spectrum activity against Gram-negative bacteria. G0775 inhibits the essential bacterial type I signal peptidase, a new antibiotic target, through an unprecedented molecular mechanism. It circumvents existing antibiotic resistance mechanisms and retains activity against contemporary multidrug-resistant Gram-negative clinical isolates in vitro and in several in vivo infection models. These findings demonstrate that optimized arylomycin analogues such as G0775 could translate into new therapies to address the growing threat of multidrug-resistant Gram-negative infections.

PMID:
30209367
DOI:
10.1038/s41586-018-0483-6

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center